Mariner, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Mariner, LLC

$58.4 Billion
Q4 2024

A detailed history of Mariner, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Mariner, LLC holds 13,666 shares of ALNY stock, worth $3.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

13,666

Previous 11,719 16.61%

Holding current value

$3.69 Million

Previous $3.22 Million 0.25%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$232.27 - $300.43 $452,229 - $584,937	1,947 Added 16.61%	13,666 $3.22 Million
Q3 2024 Nov 13, 2024	BUY	$233.81 - $287.01 $895,959 - $1.1 Million	3,832 Added 48.59%	11,719 $3.22 Million
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $142,306 - $245,271	993 Added 14.4%	7,887 $1.92 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $31,792 - $43,009	-217 Reduced 3.05%	6,894 $1.03 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $1.07 Million - $1.39 Million	-7,070 Reduced 49.86%	7,111 $1.36 Million
Q3 2023 Nov 13, 2023	SELL	$170.77 - $211.65 $623,993 - $773,369	-3,654 Reduced 20.49%	14,181 $2.51 Million
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $283,250 - $324,648	-1,531 Reduced 7.91%	17,835 $3.39 Million
Q1 2023 May 12, 2023	SELL	$182.66 - $235.53 $1.15 Million - $1.48 Million	-6,298 Reduced 24.54%	19,366 $3.88 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $144,713 - $188,221	-780 Reduced 2.95%	25,664 $6.1 Million
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $3.66 Million - $6.14 Million	26,444 New	26,444 $5.29 Million

Others Institutions Holding ALNY

# of Institutions

684

Shares Held

109M

Call Options Held

856K

Put Options Held

752K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account